That brings up an important point (re: the particular FDA branch) that Dr J mentioned. He seems a person that looks for solutions and innovative angles.

However, I didn't hear it as Dr J as saying anything about (or attacking) the relationship between the FDA and Dr NP. Instead I heard it as a broader reference to the relationship between FDA and CytoDyn- which could indicate blocks with the process, him (love Dr J's fire, precision and passion and maybe they were whiny babies about that), the end points, miscommunication, the paperwork, investor voices, the RO history, seeing dosage differently, etc. I will go back and listen again if I have time. Agree, we don't really know but I missed any sort of attack.

________________

Posted On: 05/19/2021 7:57:53 PM
Posted By: Goosebumps
Re: melsdollars #90936
Instead of attacking the relationship between the FDA and Nader as Dr J has done. I don’t know who really knows what is going on for sure. The timeline of Dr J as a science officer was short and he probably attend few meetings and to know the complete relationship would take much more evaluation I would think. We see that Nader bows to the power that is the FDA and only seeks to respect the process.

Dr. J said something interesting as a possible solution to a possible compromised relationship. Leronlimab has been classed as a viral inhibitor and that is the branch of the FDA that is reviewing Leronlimab. His suggestion is to have Leronlimab reviewed and guided by the pulmonary branch of review and receive a fresh start and his reasoning was that leronlimab in Covid is primarily a lung inflammation reducer and blocker of cells with inflammation.

Will this solve a possible problem with relationships? Who knows but it could be a fresh start and worth a suggestion. I am not convinced a short view of Dr. J is as reliable as we would hope. I think the world of him but opinions are opinions and we rationalize our relationships in different ways.


Read More: https://investorshangout.com/post/newpost/605...z6vMpBEpJY